CelLBxHealth公司为彼得·柯林斯首席执行官和新董事命名,于1月31日生效,以推进癌症诊断工作。 
CelLBxHealth names Peter Collins CEO and new directors, effective Jan. 31, to advance cancer diagnostics.
CelLBxHealth plc于2026年1月12日宣布改变领导层, 任命Peter Michael Collins为CEO, 任命Klaas De Boer、Benjamin Jacob Hart为非执行董事, CelLBxHealth plc announced leadership changes on January 12, 2026, appointing Peter Michael Collins as CEO and Klaas De Boer, Benjamin Jacob Hart, and Kimberley Anne Oreskovic as non-executive directors. Joseph Eid将在1月31日下台。 Joseph Eid will step down on January 31. 这些增加加强了董事会在生命科学和商业领导方面的专门知识,支持该公司利用其Parsortix平台执行癌症诊断任务。 The additions strengthen the board’s expertise in life sciences and business leadership, supporting the company’s mission in cancer diagnostics using its Parsortix® platform. 该公司经营一家经GCLP认证的英国实验室,侧重于四氯化碳分析,供研究和临床使用。 The company operates a GCLP-certified UK lab and focuses on CTC analysis for research and clinical use.
